Product image of Jidinum (Sitagliptin) supplied by GNH India

Jidinum

Active Ingredient:
Sitagliptin
Origin:
EU

Jidinum (Sitagliptin)

Sitagliptin, the active ingredient in Jidinum, is a Dipeptidyl peptidase-4 (DPP-4) inhibitor presented as an oral tablet for oral use. It treats type 2 diabetes mellitus in adult patients, helping to improve blood glucose control when combined with diet and exercise.

GNH India supplies Jidinum as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Medochemie Ltd.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Sitagliptin is indicated for the management of type 2 diabetes mellitus, a chronic metabolic disorder affecting glucose regulation.

  • Type 2 diabetes mellitus (monotherapy): improves glycemic control as a single oral agent.
  • Type 2 diabetes mellitus (combination therapy): enhances glucose lowering when added to metformin.
  • Type 2 diabetes mellitus (adjunct to insulin): reduces required insulin dose and helps achieve target HbA1c levels.

How It Works

  • Sitagliptin selectively inhibits the enzyme dipeptidyl peptidase‑4 (DPP‑4), which degrades the incretin hormones GLP‑1 and GIP. By blocking DPP‑4, sitagliptin raises endogenous incretin levels, leading to glucose‑dependent stimulation of insulin secretion and suppression of glucagon release, thereby lowering plasma glucose concentrations.

Side Effects

Sitagliptin is generally well tolerated, but adverse reactions can occur.

Common Side Effects

  • Nasopharyngitis: mild upper‑respiratory tract infection.
  • Headache: transient cranial discomfort.
  • Upper respiratory infection: symptoms such as cough or sore throat.
  • Gastrointestinal upset: nausea, abdominal pain or dyspepsia.
  • Dizziness: occasional light‑headedness.
  • Arthralgia: joint pain without swelling.

Serious or Rare Side Effects

  • Pancreatitis: severe abdominal pain requiring immediate medical attention.
  • Severe allergic reactions: including angioedema or anaphylaxis.
  • Bullous pemphigoid: autoimmune skin blistering disorder.
  • Hepatic injury: elevated liver enzymes or hepatitis.
  • Severe hypoglycemia: especially when combined with insulin or sulfonylureas.
  • Stevens‑Johnson syndrome: rare but life‑threatening skin reaction.

Precautions & Warnings

Before initiating sitagliptin therapy, consider the following safety measures.

  • Renal function: assess creatinine clearance and adjust dose if necessary.
  • Hepatic function: monitor liver enzymes in patients with existing liver disease.
  • Cardiovascular disease: use with caution in patients with a history of heart failure.
  • Concomitant insulin or sulfonylureas: increased risk of hypoglycemia; monitor glucose closely.
  • Pregnancy and lactation: safety not established; avoid unless benefits outweigh risks.
  • Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Avoid Interactions

Sitagliptin may interact with other medicines, altering its efficacy or safety.

Major Interactions (Avoid)

  • Insulin or sulfonylureas: heightened risk of hypoglycemia.
  • Strong CYP2C8 inhibitors (e.g., gemfibrozil): increase sitagliptin plasma concentrations.
  • Strong CYP3A4 inducers (e.g., rifampin): reduce sitagliptin exposure and effectiveness.

Moderate Interactions (Monitor Closely):\n- ACE inhibitors: possible additive hypotensive effect.

  • Diuretics: monitor renal function and electrolytes.
  • NSAIDs: may affect renal clearance of sitagliptin, especially in compromised patients.

Frequently Asked Questions

Jidinum contains sitagliptin, a DPP‑4 inhibitor indicated for the treatment of type 2 diabetes mellitus in adults. It helps lower blood glucose levels when used together with diet, exercise, and other antidiabetic agents as prescribed by a healthcare professional.

Sitagliptin blocks the enzyme dipeptidyl peptidase‑4, which normally degrades the incretin hormones GLP‑1 and GIP. By inhibiting DPP‑4, sitagliptin raises endogenous incretin levels, leading to glucose‑dependent insulin release and reduced glucagon secretion, thereby improving glycemic control.

The dosage of Jidinum is individualized by the prescribing clinician based on the patient’s renal function, glycemic targets, and concomitant therapies. Patients should follow the exact dosing instructions provided by their healthcare professional.

Safety of sitagliptin in pregnancy and lactation has not been established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and this decision must be made by the treating physician.

To place an order, submit an enquiry on the Jidinum product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Compared with sulfonylureas, sitagliptin has a lower risk of causing hypoglycemia because its insulin‑stimulating effect is glucose‑dependent. Unlike metformin, it does not affect gastrointestinal tolerance as markedly, and it can be combined with both agents for additive glucose‑lowering effects.

Store Jidinum at room temperature, below 25 °C. Keep the tablets in the original blister pack, protect them from moisture and direct sunlight, and ensure the container is tightly closed to maintain product stability.

Jidinum is taken orally, usually once daily, with or without food. The tablet should be swallowed whole with a glass of water and not chewed or crushed, unless otherwise directed by a healthcare professional.

Serious risks include pancreatitis, severe allergic reactions such as anaphylaxis, bullous pemphigoid, and rare hepatic injury. Patients should seek immediate medical attention if they experience persistent abdominal pain, rash, or signs of an allergic reaction.

Jidinum is contraindicated in patients with a known hypersensitivity to sitagliptin or any component of the formulation. Caution is also advised for individuals with severe renal impairment, uncontrolled heart failure, or a history of pancreatitis, and it should be avoided in pregnancy unless clearly indicated.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Sitagliptin

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT